How Medtech Companies Can Reach Physicians and Health System Decision-Makers by Email in 2026

Cold email still works for reaching physicians and health system executives, but only when it is done with discipline. Average reply rates have fallen to the low single digits, and healthcare buyers are harder to reach than almost any other B2B audience because they are time-starved, guarded, and ignore generic messaging. Medtech companies that break through fix deliverability first, write to one specialty at a time, lead with clinical and economic evidence the buying committee cares about, build credibility before the email lands, and follow up far longer than most teams do. This guide covers the benchmarks, why healthcare email is different, and the playbook that moves reply rates from about 3% toward 15% and higher.

‍

Key Takeaways

• Average B2B cold email reply rates have slid from about 6.8% in 2023 to 3.4-5.8% in recent benchmarks, and healthcare buyers sit at the harder end of that range.
• An estimated 84% of physicians ignore standardized marketing materials, so generic email blasts are close to worthless.
• Deliverability is the first lever, not copy. If a large share of your emails never reach the inbox, no subject line will save the campaign.
• Tight lists win: campaigns of 50 recipients or fewer averaged 5.8% replies versus 2.1% for lists of 500 or more (Belkins).
• Signal-based personalization can reach about 18% reply rates, roughly 5x the generic average, and disciplined follow-up sequences are where most of the upside lives.

What Is a Realistic Cold Email Reply Rate When Emailing Physicians and Health Systems?

Lower than most medtech leaders expect, and declining. Across general B2B, average cold email reply rates have fallen from roughly 6.8% in 2023 to the 3.4-5.8% range in recent benchmarks from Belkins, Instantly, Hunter, and Martal Group, driven by inbox saturation, stricter spam filtering, and a flood of low-effort AI-generated outreach.

‍

Healthcare buyers respond at or below that baseline. Even before COVID, getting 15 minutes on a hospital administrator's or clinician's calendar was difficult; staffing shortages and tighter access protocols have only raised the bar. The flip side is that about 61% of decision-makers say they prefer email over phone or LinkedIn, so the channel is the right one. The challenge is earning a reply from a guarded, overloaded reader. Below 3% means something is broken, 3-5% is realistic for a competent team at scale, 5-8% is strong, and 10% or higher is elite, reserved for tight lists and hyper-relevant messaging. To see what these benchmarks mean for your own list size and outreach targets, use the calculator below this article to estimate your projected opens, replies, and meetings.

‍

Why Do Physicians and Hospital Executives Ignore Cold Emails?

Because most of what lands in their inbox is not relevant to them. Industry surveys suggest around 84% of physicians ignore standardized marketing materials, yet most medtech companies still email identical content to their entire database. With more than 157 recognized medical specialties, one generic message cannot speak to a general surgeon, a urologist, and a gynecologist at once, because each weighs different outcomes.

‍

Medtronic's Hugo robotic system rollout shows the payoff of relevance: general surgeons cared most about operative-time reduction, gynecologists about patient satisfaction, and urologists about nerve-sparing outcomes. Building distinct, specialty-specific messaging reportedly drove adoption roughly 45% higher than a one-size-fits-all approach. In a physician's inbox, specificity is the difference between a read and a delete.

‍

How Many Follow-Up Emails Does It Take to Reach a Healthcare Decision-Maker?

More than most teams send. Nearly half of cold outreach sequences are only a single email, and that is where most medtech pipelines quietly die. Backlinko's analysis found that emailing the same contact multiple times produced roughly 2x the responses, and Belkins data shows a first follow-up can lift B2B response rates by as much as 50%.

‍

There is a ceiling, though. Belkins found the third follow-up tends to underperform the original email, so the sweet spot is a sequence of two to three well-spaced, value-adding touches rather than endless pinging. Spacing matters too: following up a few days after the initial send, and again after an open, tends to perform best. Persistence works only when each email gives the reader a new reason to engage.

‍

Does Email Deliverability Matter for Medtech Outreach?

It is the precondition for everything else. If a meaningful share of your emails never reach the primary inbox, no amount of personalization or clever copy will rescue the campaign. Aim for 95% deliverability or higher before you optimize anything else.

‍

This is no longer optional. Since February 2024, Google and Yahoo have enforced strict authentication requirements for bulk senders, and as of late 2025 Gmail actively rejects non-compliant mail rather than just filtering it to spam; Microsoft has followed for Outlook.com. The non-negotiables are SPF, DKIM, and DMARC authentication, spam-complaint rates under 0.3%, bounce rates under 2%, and one-click unsubscribe headers. Teams that have not adapted are watching their cold emails silently disappear before a physician ever sees them.

‍

The Medtech Cold Email Playbook

1. Fix deliverability first

Authenticate your domain (SPF, DKIM, DMARC), warm up sending infrastructure, keep lists clean and verified, and monitor bounce and complaint rates. This is unglamorous, and it is the single highest-leverage thing most medtech teams can do, because inbox placement gates every other tactic below.

‍

Segment physicians by specialty, affiliation, referral pattern, and procedure volume, then write copy aimed at that segment's specific outcomes. A message built for high-volume knee-replacement orthopedic surgeons should read nothing like one for interventional cardiologists. Relevance, not reach, is what earns the reply.

‍

Hospitals and health systems buy through value analysis committees that include clinicians, procurement, finance, and increasingly IT. Under sustained financial strain (U.S. hospital labor costs alone rose an estimated $42.5 billion between 2021 and 2023), every purchase must show a clear return. Your email should move past what the device does to why it matters clinically, operationally, and financially: procedure-level outcomes, length-of-stay and complication data, and a defensible economic story tied to the specific institution.

‍

Healthcare buyers research vendors long before they reply to one, so your cold email should not actually be cold. Peer validation is the strongest opener: referencing a respected physician's results, a KOL-backed case study, or how a comparable institution succeeded with your solution softens skepticism fast. Owned content such as published insights, thought leadership, podcasts, and webinars does the credibility work in advance, so the name in the inbox is already familiar.

‍

Long emails lose busy clinicians. Recent benchmarks put the optimal length at roughly 50 to 125 words, with reply rates about 50% higher than longer formats. One clear, relevant point and one clear ask beats a wall of features. Put a calendar link in your signature rather than burying it in the body.

‍

6. Sequence the follow-ups, and do not quit early

‍

Build a planned two-to-three-email sequence, space the touches a few days apart, and make each one add value (a new data point, a relevant case study, a peer reference) rather than just circling back. This is where most of the realistic upside lives, since the majority of replies nevercome from the first email.y.

7. Narrow the list and personalize on signals

Smaller campaigns dramatically outperform blasts. Belkins found lists of 50 or fewer averaged 5.8% replies versus 2.1% for 500 or more. Within a target account, contacting two to four relevant people can lift response rates to nearly 8%, while emailing five to ten contacts at the same organization drops it to around 2.5% and reads as spam. Layer in signal-based personalization, such as a recent procedure-volume trend, a new service line, a leadership change, or a published outcome, and reply rates climb toward the 18% that signal-specific campaigns can achieve.

The Bottom Line for Medtech Leaders

Cold email to physicians and health systems is not a volume problem. It is a deliverability, relevance, and persistence problem. The medtech companies filling their pipelines have stopped blasting databases and started running email as a research-led system: authenticated infrastructure, specialty-specific copy, committee-ready evidence, credibility built in advance, and disciplined follow-up. Get those right and you move from the 3-5% baseline toward the 15% and higher that top performers reach. Use the calculator below to benchmark where your current outreach stands and model the upside of a tighter, evidence-led approach.
‍